Jayani Pathirana1,2, Michelle Groome1,2, Jeffrey Dorfman1,2, Gaurav Kwatra1,2, Suresh Boppana3,4, Clare Cutland1,2, Stephanie Jones1,2, Shabir A Madhi1,2. 1. Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa. 2. Department of Science/National Research Foundation, Vaccine Preventable Diseases, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa. 3. Department of Pediatrics, University of Alabama School of Medicine, Birmingham. 4. Department of Microbiology, University of Alabama School of Medicine, Birmingham.
Abstract
BACKGROUND: There is a paucity of data on the burden of congenital cytomegalovirus (cCMV) infections in low- and middle-income countries, including their association with maternal human immunodeficiency virus (HIV) infections. We investigated the prevalence of cCMV in a patient population with a high rate of HIV and antiretroviral therapy (ART) use during pregnancy in Soweto, Johannesburg. METHODS: Saliva from neonates were screened for cytomegalovirus (CMV) infection by polymerase chain reaction (PCR) at birth. Additional saliva and urine samples were tested within 3 weeks of birth to confirm positive saliva results. HIV PCR testing was done on the whole blood of HIV-exposed neonates. Maternal and neonatal data were extracted from clinical records. RESULTS: Of 2685 neonates screened for cCMV, 828 (31%) were born to HIV-infected women, 95% of whom (790/828) were on ART at delivery. The overall prevalence of cCMV was 2.5% (95% confidence interval [CI] 1.9-3.2), with significantly higher cCMV prevalence in HIV-exposed neonates (5.2%, 95% CI 3.8-6.9) than HIV-unexposed neonates (1.4%, 95% CI 0.9-2.0). The risk of in utero HIV infection was 20-fold greater (odds ratio 20.1, 95% CI 6.09-66.46) in HIV-exposed, cCMV-infected neonates, and this increased risk was not associated with the maternal CD4+ T-cell count or the maternal duration of ART. CONCLUSIONS: The prevalence of cCMV in our setting is substantially higher than the global estimate of 0.64%, partly due to the increased susceptibility for cCMV in HIV-exposed neonates. The significantly increased risk of in utero HIV infection in neonates with cCMV indicates that CMV coinfection plays a major role in the residual burden of in utero HIV transmission, even in the era of ART.
BACKGROUND: There is a paucity of data on the burden of congenital cytomegalovirus (cCMV) infections in low- and middle-income countries, including their association with maternal human immunodeficiency virus (HIV) infections. We investigated the prevalence of cCMV in a patient population with a high rate of HIV and antiretroviral therapy (ART) use during pregnancy in Soweto, Johannesburg. METHODS: Saliva from neonates were screened for cytomegalovirus (CMV) infection by polymerase chain reaction (PCR) at birth. Additional saliva and urine samples were tested within 3 weeks of birth to confirm positive saliva results. HIV PCR testing was done on the whole blood of HIV-exposed neonates. Maternal and neonatal data were extracted from clinical records. RESULTS: Of 2685 neonates screened for cCMV, 828 (31%) were born to HIV-infectedwomen, 95% of whom (790/828) were on ART at delivery. The overall prevalence of cCMV was 2.5% (95% confidence interval [CI] 1.9-3.2), with significantly higher cCMV prevalence in HIV-exposed neonates (5.2%, 95% CI 3.8-6.9) than HIV-unexposed neonates (1.4%, 95% CI 0.9-2.0). The risk of in utero HIV infection was 20-fold greater (odds ratio 20.1, 95% CI 6.09-66.46) in HIV-exposed, cCMV-infected neonates, and this increased risk was not associated with the maternal CD4+ T-cell count or the maternal duration of ART. CONCLUSIONS: The prevalence of cCMV in our setting is substantially higher than the global estimate of 0.64%, partly due to the increased susceptibility for cCMV in HIV-exposed neonates. The significantly increased risk of in utero HIV infection in neonates with cCMV indicates that CMV coinfection plays a major role in the residual burden of in utero HIV transmission, even in the era of ART.
Authors: Samuel Mundia Kariuki; Philippe Selhorst; Jennifer Norman; Karen Cohen; Kevin Rebe; Carolyn Williamson; Jeffrey R Dorfman Journal: Virol J Date: 2020-03-05 Impact factor: 4.099
Authors: Natasha O Moraka; Sikhulile Moyo; Christiana Smith; Maryanne Ibrahim; Gloria Mayondi; Jean Leidner; Kathleen M Powis; Adam R Cassidy; Betsy Kammerer; Gbolahan Ajibola; Paige L Williams; Adriana Weinberg; Rosemary Musonda; Roger Shapiro; Simani Gaseitsiwe; Shahin Lockman Journal: Open Forum Infect Dis Date: 2020-08-22 Impact factor: 3.835
Authors: Paddy Ssentongo; Christine Hehnly; Patricia Birungi; Mikayla A Roach; Jada Spady; Claudio Fronterre; Ming Wang; Laura E Murray-Kolb; Laila Al-Shaar; Vernon M Chinchilli; James R Broach; Jessica E Ericson; Steven J Schiff Journal: JAMA Netw Open Date: 2021-08-02
Authors: Christine Hehnly; Paddy Ssentongo; Lisa M Bebell; Kathy Burgoine; Joel Bazira; Claudio Fronterre; Elias Kumbakumba; Ronald Mulondo; Edith Mbabazi-Kabachelor; Sarah U Morton; Joseph Ngonzi; Moses Ochora; Peter Olupot-Olupot; John Mugamba; Justin Onen; Drucilla J Roberts; Kathryn Sheldon; Shamim A Sinnar; Jasmine Smith; Peter Ssenyonga; Julius Kiwanuka; Joseph N Paulson; Frederick A Meier; Jessica E Ericson; James R Broach; Steven J Schiff Journal: Int J Infect Dis Date: 2022-02-09 Impact factor: 12.074